About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Endobronchial Lipoma: An Unusual Cause of Obstructive Pulmonary Pathology

ventolin hfa

ventolin over the counter philippines

how are abortions performed

buy abortion pill
Swati Agarwal1, Devesh Chauhan2, Shalini Mullick1, RK Dewan3, Kumud Gupta1
From the Department of Pathology1, Radiology2 and Thoracic Surgery3; National Institute of Tuberculosis and Respiratory Diseases, Sri Aurbindo Marg, New Delhi-30, India.
Corresponding Author:
Dr. Swati Agarwal
Email: drswatiagr@yahoo.com
Received: 22-AUG-2013 Accepted: 19-JAN-2014 Published Online: 30-JAN-2014
DOI: http://dx.doi.org/10.17659/01.2014.0012
Abstract
Endobronchial lipomas are uncommon and account for only 0.1-0.5% of all lung neoplasms. They are usually detected on chest X-ray and CT scan. These are benign neoplasms with no malignant potential and almost negligible local recurrence. Endobronchial resection is usually adequate, but sometimes patients present with obstructive pulmonary pathology and extensive surgery may be required.
Keywords : Lipoma, Lung Neoplasms, Pneumonia, Bronchoscopy, Bronchiectasis, Pulmonary Atelectasis.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 19, 2025